Compare Monster Beverage Corp (MNST) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Natera Inc. Common Stock — how do they compare? Monster Beverage Corp trades at $44.82 (market cap $84.85B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Monster Beverage Corp is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Natera Inc. Common Stock for 0 Days on average.
| MNST | NTRA | |
|---|---|---|
Market Cap | $84.85B | $57.03B |
Volume | 7,847,331 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $425.64 |
52-Week Low | $33.16 | $179.42 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $83.14B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $44.22, up 1.05% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust fundamentals including 55.55% gross margin and 23.08% net margin. Recent news highlights international growth, a debt-free balance sheet, and a 1:2 stock split effective August 2026.
Outlook remains positive with analyst consensus target of $98.22 implying significant upside, supported by international expansion and high profitability. Key risks include valuation multiples above industry averages and regulatory challenges in markets like India. The stock's growth trajectory is solid, but investors should weigh rich valuations against execution risks.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
